Inventor · disambiguated record
Eugenio A. Cefali
Also filed as: CEFALI EUGENIO · CEFALI EUGENIO A
7 granted patents·16 pending applications·308 citations·filing 1989–2017
89Inventor score
Top patents by PatentIndex Score
23 records- 0187US4992277AImmediate release diltiazem formulationSCHERING CORP·Filed 1989·Granted Feb 12, 1991·86 cites·3 claims
- 0285US6676967B1Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemiaKOS PHARMA INC·Filed 1997·Granted Jan 13, 2004·40 cites·27 claims
- 0376US5000962ALong acting diltiazem formulationSCHERING CORP·Filed 1989·Granted Mar 19, 1991·48 cites·4 claims
- 0475US6469035B1Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acidFiled 1997·Granted Oct 22, 2002·49 cites·30 claims
- 0575US2010076033A1Methods For Treating Hyperlipidemia with Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical CharacteristicsCEFALI EUGENIO·Filed 2009·Application pending·0 cites
- 0673US2009054499A1Intermediate Release Nicotinic Acid Compositions For Treating Hyperlipidemia Which Exhibit an In Vivo Stair-Stepped Absorption CurveCEFALI EUGENIO A·Filed 2008·Application pending·0 cites
- 0770US2007232667A1Methods for Treating Hyperlipidemia With Intermediate Release Nicotinic Acid Compositions Having Unique Biopharmaceutical CharacteristicsCEFALI EUGENIO·Filed 2007·Application pending·0 cites
- 0867US2006263428A1Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristicsCEFALI EUGENIO·Filed 2006·Application pending·0 cites
- 0967US2010240899A1Intermediate release nicotinic acid compositions for treating hyperlipidemia which exhibit an in vivo stair-stepped absorption curveCEFALI EUGENIO A·Filed 2009·Application pending·0 cites
- 1066US6406715B1Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profilesKOS PHARMA INC·Filed 1997·Granted Jun 18, 2002·31 cites·16 claims
- 1165US2009069275A1Low flush niacin formulationROCCA JOSE G·Filed 2008·Application pending·0 cites
- 1264US6818229B1Intermediate release nicotinic acid compositions for treating hyperlipidemiaKOS PHARMA INC·Filed 1997·Granted Nov 16, 2004·28 cites·28 claims
- 1364US2013005779A1Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristicsCEFALI EUGENIO A·Filed 2012·Application pending·0 cites
- 1462US6746691B2Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristicsKOS PHARMA INC·Filed 1997·Granted Jun 8, 2004·26 cites·21 claims
- 1557US2012157685A1Intermediate release nicotinic acid compositions for treating hyperlipidemia which exhibit an in vivo stair-stepped absorption curveCEFALI EUGENIO A·Filed 2012·Application pending·0 cites
- 1656US2013344144A1Low flush niacin formulationABBVIE INC·Filed 2013·Application pending·0 cites
- 1756US2012035225A1Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristicsCEFALI EUGENIO·Filed 2011·Application pending·0 cites
- 1856US2012202855A1Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristicsCEFALI EUGENIO A·Filed 2011·Application pending·0 cites
- 1954US2003157153A1Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristicsKOS PHARMA INC·Filed 2002·Application pending·0 cites
- 2054US2003161880A1Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristicsKOS PHARMA INC·Filed 2002·Application pending·0 cites
- 2153US2008050429A1Low flush niacin formulationROCCA JOSE G·Filed 2007·Application pending·0 cites
- 2247US2014113939A1Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristicsABBOTT LAB·Filed 2012·Application pending·0 cites
- 2333US2019282560A11-Methylnicotinamide for the Treatment of Diseases Associated With C-Reactive ProteinPHARMENA S A·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Eugenio A. Cefali files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →